This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ries, C. Articles by Petrides, P. E. Search for Related Content PubMed PubMed Citation Articles by Ries, C. Articles by Petrides, P. E.

Matrix Metalloproteinase Production by Bone Marrow Mononuclear Cells from Normal Individuals and Patients with Acute and Chronic Myeloid Leukemia or Myelodysplastic Syndromes¹

Molecular Oncology Laboratory, Department of Medicine III, University of Munich Medical School Grosshadern, L81377 M Munich [C. R., F. L., C. Z., M. G. I., P. E. P.]; Molecular Oncology Laboratory, Department of Medicine II, Charité Medical School of Humboldt-University, 10117 Berlin [C. Z., P. E. P.]; and Institute for Clinical Hematology, GSF-National Research Center for Environment and Health, L81377 M Munich [M. G. I.], Germany

The two matrix metalloproteinases (MMPs) M_r 72,000 type IV collagenase (MMP-2, gelatinase A) and M_r 92,000 type IV collagenase (MMP-9, gelatinase B) play key roles in tissue remodeling and tumor invasion by digestion of extracellular matrix barriers. We have investigated the production of these two enzymes as well as the membrane-type MMP (MT1-MMP) and the tissue inhibitors of metalloproteinases (TIMPs) TIMP-1 and TIMP-2 in the bone marrow mononuclear cells (BM-MNCs) of patients with acute myeloid leukemia (AML; n = 24), chronic myeloid leukemia (CML; n = 17), myelodysplastic syndromes (MDS; n = 8), and healthy donors (n = 5). Zymographic analysis of BM-MNC-conditioned medium showed that a M_r 92,000 gelatinolytic activity, identified as MMP-9 by Western blotting, was constitutively released from cells of all patients and healthy individuals examined in this study. In contrast, MMP-2 secretion was found to be absent in all samples from healthy donors but present in 8 of 11 (73%) of the samples from patients with primary AML, 7 of 8 (88%) with secondary AML, and only 1 of 5 (20%) cases with AML in remission, indicating MMP-2 to be produced by the leukemic blasts. MMP-2 release was not detected in CML cell-conditioned medium with the exception of two cases, both patients either being in or preceding blast crisis. In MDS, MMP-2 was found in three of eight (38%) of the patients, two of them undergoing progression of disease within 12 months. Quantitative Northern blot analysis in freshly isolated BM-MNCs showed a relatively low constitutive expression of TIMP-1 in all samples, whereas MMP-9 gene transcription was higher in healthy donors and CML samples, than in AML and MDS. Reverse transcriptase-PCR analysis revealed the presence of TIMP-2 mRNA in the majority of MMP-2-releasing BM-MNCs. MT1-MMP expression was present in most samples of patients with MDS or AML but absent in those with secondary AML and CML. Thus, we have shown that BM-MNCs continuously produce MMP-9 and TIMP-1 and demonstrated that leukemic blast cells additionally secrete MMP-2 representing a potential marker for dissemination in myeloproliferative malignancies.

This article has been cited by other articles:

				S. Monteghirfo, F. Tosetti, C. Ambrosini, S. Stigliani, S. Pozzi, F. Frassoni, G. Fassina, S. Soverini, A. Albini, and N. Ferrari Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-{kappa}B and p53 modulation Mol. Cancer Ther., September 1, 2008; 7(9): 2692 - 2702. [Abstract] [Full Text] [PDF]

				M. Iwata, M. Pillai, A. Ramakrishnan, R. C. Hackman, H. J. Deeg, G. Opdenakker, and B. Torok-Storb Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity Blood, January 1, 2007; 109(1): 85 - 92. [Abstract] [Full Text] [PDF]

				M. Nieborowska-Skorska, G. Hoser, L. Rink, M. Malecki, P. Kossev, M. A. Wasik, and T. Skorski Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells. Cancer Res., April 15, 2006; 66(8): 4108 - 4116. [Abstract] [Full Text] [PDF]

				M. Xu, E. Bruno, J. Chao, S. Huang, G. Finazzi, S. M. Fruchtman, U. Popat, J. T. Prchal, G. Barosi, R. Hoffman, et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases Blood, June 1, 2005; 105(11): 4508 - 4515. [Abstract] [Full Text] [PDF]

				R. K. Narla, Y. Dong, D. Klis, and F. M. Uckun Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) as a Novel Antileukemic Agent with Matrix Metalloproteinase Inhibitory Activity Clin. Cancer Res., April 1, 2001; 7(4): 1094 - 1101. [Abstract] [Full Text]